drugset / Trial / NCT05281068
The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Phase 2
Unknown
120 enrolled
Peking University People's Hospital
Beijing Friendship Hospital · collabBeijing Hospital · collabChina-Japan Friendship Hospital · collabFirst Affiliated Hospital of Chongqing Medical University · collabShanxi Bethune Hospital · collabThe First Affiliated Hospital of Zhengzhou University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized, open-label, multicenter study to compare the efficacy and safety of combination of iguratimod and danazol versus danazol for the treatment of adults with steroid-resistant/ relapse immune thrombocytopenia (ITP).
Timeline
- Start
- 2021-09-01
- Primary completion
- 2023-09-01
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danazol | Other / unclassified | 200 mg | Oral |
| Subject | Iguratimod | Small molecule | 25 mg | Oral |